Parameter
| Biomarker | NTRK (fusion) | Full name | Neurotrophic tyrosine receptor kinase fusions | Molecular Type | Nucleic acid (DNA fusion) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Targeted therapy options | ||
| Disease | Cholangiocarcinoma (CCA) | Disease Subtypes | / | ||
| Organ | Bile duct/Liver | Test Sample / Technology Platform | Tissue/Plasma (NGS) | ||
| Pathobiological Mechanisms | Fusion activates the TRK signaling pathway and promotes tumor growth | ||||
| Clinical Availability Status | Clinical validation (tumor-agnostic therapy); Rare (<1%) | ||||
| Notes and Dynamics | Larotrectinib, entrectinib approved, ORR 75%; ctDNA testing can assist in screening patients and avoid invasive biopsy | ||||